Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: Comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 1, 2004, Pages 37-44

  Prontera, Concetta ^a   Emdin, Michele ^a   Zucchelli, Gian Carlo ^a   Ripoli, Andrea ^a   Passino, Claudio ^a   Clerico, Aldo ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); Electrochemiluminescent assay (ECLIA); Functional sensitivity; Heart failure; Immunoradiometric assay (IRMA); Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGE; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CARDIOMYOPATHY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GENDER; HEART FAILURE; HUMAN; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; AUTOMATION; CARDIOMYOPATHIES; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HUMANS; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; LINEAR MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 1642525276     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.008     Document Type: Article

References (42)

1. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular diseases. Clin Sci 1998;95:519-29.
2. Clerico A, Iervasi G, Mariani G. Clinical relevance of the measurement of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-98.
3. Boomsma F, Van den Meiracker AH. Plasma A- and B-type natriuretic peptides: Physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-9.
4. Suzuki T, Yamazaki T, Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 2001;51:489-94.
5. Mair J, Hammerer-Lercher A, Puchendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88.
6. Maisel A. B-type natriuretic peptide levels: A potential novel ΦwHite count" for congestive heart failure. J Cardiac Failure 2001;7:183-93.
7. Chen HH, Burnett JC Jr. Natriuretic peptides in the pathophysiology of congestive heart failure. Cur Cardiol Rep 2000;2:198-205.
8. Struthers AD. Introducing a new role for BNP: As a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2002;87:97-8.
9. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002;87:131-5.
10. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Col Cardiol 2001;38:1934-41.
11. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recording. Circulation 2002;105:595-601.
12. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-9.
13. Cabanes L, Richaaud-Thiriez B, Fulla Y, Heloire F, Vuillemard C, Weber S, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001;120:2047-50.
14. Remme WJ, Swedberg K. Task Force Report. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
15. Friesinger GC. Cardiovascular disease in the elderly. Cardiol Clin 1999;17:35-49.
16. Katz AM. Heart failure. Pathophysiology, molecular biology, and clinical management. Philadelphia: Lippincott Willians & Wilkins, 2000:1-380.
17. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: Is their assay merely a marker of cardiac disease? Clin Chem Lab Med 2002;40:752-60.
18. Clerico A, Del Ry S, Giannessi D. Measurement of natriuretic cardiac hormones (ANP, BNP, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000;46:1529-34.
19. Clerico A, Iervasi G, Del Ry S, Giannessi D. Immunoassay methods for the measurement of natriuretic cardiac hormones (ANP, BNP, and related peptides) in humans. J Clin Ligand Assay 1999;22:194-204.
20. Clerico A, Del Ry S, Giannessi D, Trianni G, Rizza A, Botto N, et al. Evaluation and comparison of commercial immunoassay methods for the determination of N-terminal proANP in plasma and atrial tissue. J Clin Ligand Assay 2001;24:112-8.
21. Hughes D, Talwar S, Squire IB, Davies JE, NG LL. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci 1999;96:373-80.
22. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand L Clin Lab Invest 1999;59 (Suppl 230):177-81.
23. Del Ry S, Giannessi D, Clerico A. Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric assay compared. Clin Chem Lab Med 2001;39:446-50.
24. Masson S, Vago T, Baldi G, Salio M, DeAngelis N, Nicolis E, et al. Comparative measurement of N-terminal probrain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 2002;40:761-3.
25. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Fully-automated NT-proBNP and IRMA methods for BNP and ANP in heart failure and healthy subjects. Clin Chem 2003;49:1552-4.
26. Bossuyt PM, Reitsma JB, Bruns DE, Gatstonis CA, Glaszious PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Clin Chem 2003;49:1-6.
27. Bossuyt PM, Reitsma JB, Bruns DE, Gatstonis CA, Glaszious PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration. Clin Chem 2003;49:7-18.
28. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D. Circulating levels of cardiac natriuretic hormones in healthy adult subjects: Effects of aging and sex. Clin Chem Lab Med 2002;40:371-7.
29. Clerico A, Iervasi G, Del Chicca MG, Maffei S, Berti S, Sabatino L, et al. Analytical performance and clinical usefulness of a commercially available IRMA kit for the measurement of atrial natriuretic peptide in patients with heart failure. Clin Chem 1996;42:1627-33.
30. Clerico A, Iervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;21:170-9.
31. Del Ry S, Clerico A, Giannessi D, Andreassi MG, Caprioli R, Iascone MR, et al. Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an IRMA method. Scand J Clin Lab Invest 2000;60:81-90.
32. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988;44:837-45.
33. Platt RW, Hanley JA, Yang H. Bootstrap confidence intervals for the sensitivity of a quantitative diagnostic test. Statist Med 2000;19:313-22.
34. NCCLS Guideline EP5-A. Evaluation of precision performance of clinical chemistry devices; approved guideline. NCCLS 1999;19:1-50.
35. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays [review]. Clin Chem 1996;42:140-5.
36. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
37. Nageh T, Chin D, Cooke JC, Meehan N, Monaghan MJ, Sherwood RA. Interpretation of plasma brain natriuretic peptide concentration may require adjustment for patient's age. Ann Clin Biochem 2002;39:151-3.
38. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PWF, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-8.
39. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review. Clin Chem 50; January.
40. Bluestein BI, Belenky A, Lin S, Despres N, Vajdi M, Armstrong G. Development of an automated test for B-type natriuretic peptide (BNP) as an aid in the diagnosis and evaluation of congestive heart failure on the Bayer ADVIA Centaur chemiluminescent system [abstract]. Clin Chem 2002;48 (Suppl. to n. 6):A85.
41. Kelly PM, Gaston S, Mackay R, Arthur K, Taylor V, Shik J, et al. A novel assay for the measurement of plasma B-type natriuretic peptide by an AxSYM microparticle based immunoassay with use of stable liquid calibrators. [abstract]. Clin Chem 2002;48(Suppl. to n. 6):A94.
42. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001;310:193-7.